ABOUT US
Introduction
Chairman's Statement
Contact Us
R&D
R&D Platforms
R&D Capability
R&D Center
Scientific Activities
PRODUCTS
bFGF Series
other ophthalmic products
other surgical products
NEWS
company news
investee news
media focus
INVESTOR RELATIONS
Announcements & Shareholder Info
Corporate Info
Financial & ESG Reports
Contact Us
CAREERS
Talent Concept
Job Opportunities
简
繁
EN
ABOUT US
Introduction
Chairman's Statement
Contact Us
R&D
R&D Platforms
R&D Capability
R&D Center
Scientific Activities
PRODUCTS
bFGF Series
other ophthalmic products
other surgical products
NEWS
company news
investee news
media focus
INVESTOR RELATIONS
Announcements & Shareholder Info
Corporate Info
Financial & ESG Reports
Contact Us
CAREERS
Talent Concept
Job Opportunities
简
繁
EN
简
繁
EN
COMPANY NEWS
Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2020
2020.11.23
Time
Last 7 days
Last 30 days
The last six months
Date
Title
2019-12-12
Essex Bio-Technology and Mitotech Announce First Patient First Visit in U.S. FDA Second Phase 3 Clinical Trial of SkQ1
2019-08-21
Admission of Product to the PRC National Drug List for Reimbursement, Beifuxin Newly Listed and the Other Three Products Remain on the List
2019-08-12
Essex Biotech's mid-2019 net profit increased by 31% year-on-year to HK$129 million
2019-08-02
Essex Bio-Technology and Antikor Biopharma Forge Strategic Alliance in FDC for Cancer Treatment
2019-07-19
Essex Bio-Technology and Mitotech Announce Topline Results from VISTA-1, Phase 3 Clinical Trial in U.S. FDA of a First-In-Class Drug for Dry Eye Disea
2019-05-15
Essex Bio-Technology Included by MSCI as A Constituent of The MSCI China Small Cap Index
2019-04-29
Essex Bio-Technology Announces Upcoming Joint Presentation with Mitotech and Ora at ARVO 2019 Annual Meeting
2019-03-12
FY18 Turnover & Net Profit grew 30.8% and 38.1% to HK$1,176.5 million & HK$ 231.1 million, respectively
<
1
2
3
4
>
